EMEND IV

This brand name is authorized in Australia, Brazil, Canada, Hong Kong SAR China, Mexico, Singapore.

Active ingredients

The drug EMEND IV contains one active pharmaceutical ingredient (API):

1	Fosaprepitant UNII D35FM8T64X - FOSAPREPITANT DIMEGLUMINE
	Fosaprepitant is the prodrug of aprepitant and when administered intravenously is converted rapidly to aprepitant. The contribution of fosaprepitant to the overall antiemetic effect has not fully been characterised, but a transient contribution during the initial phase cannot be ruled out.
	Read more about Fosaprepitant

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
EMEND IV Fosaprepitant for injection	MPI, CA: SPM	Health Products and Food Branch (CA)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
A04AD12	Aprepitant	A Alimentary tract and metabolism → A04 Antiemetics and antinauseants → A04A Antiemetics and antinauseants → A04AD Other antiemetics
Discover more medicines within A04AD12

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	11103J, 11107N
BR	Câmara de Regulação do Mercado de Medicamentos	525513060015502
CA	Health Products and Food Branch	02363356
HK	Department of Health Drug Office	61194
MX	Comisión Federal para la Protección contra Riesgos Sanitarios	140M2010
SG	Health Sciences Authority	14150P